With a potential treatment for Alzheimer’s disease, a deal to co-develop a proven-effective COVID-19 vaccine for the U.S. market, and a platform of red-blood-cell-based cancer therapies, the three biotech stocks featured in today’s article have all posted massive year-to-date gains – but the author warns that they could prove to be toxic additions to your portfolio. Why? CLICK HERE.
Contraindicated: Why These 3 Biotech Stocks With Massive Gains Could Be Toxic For Portfolios
- by RobH